Evidence map›Paper›PMID 38561199›Full record

ArticleInfection control and hospital epidemiology2024

Separating the rash from the chaff: novel clinical decision support deployed during the mpox outbreak.

Jacob E Lazarus, Chloe V Green, Michelle S Jerry, Lindsay Germaine, Dustin S McEvoy, Caitlin M Dugdale, Kristen M Hysell, Rebecca L Craig, Molly L Paras, Howard M Heller and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Infection control and hospital epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jacob E LazarusDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-9286-3548
Chloe V GreenDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Michelle S JerryDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Lindsay GermaineClinical Informatics and Decision Support, Digital Health, Mass General Brigham, Somerville, MA, USA.
Dustin S McEvoyClinical Informatics and Decision Support, Digital Health, Mass General Brigham, Somerville, MA, USA.ORCID 0000-0002-5860-1541
Caitlin M DugdaleDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-6604-6111
Kristen M HysellDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Rebecca L CraigInfection Control Unit, Massachusetts General Hospital, Boston, MA, USA.
Molly L ParasDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-6658-8634
Howard M HellerDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Kevin L ArdDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
John S AlbinDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-6523-7744
Hang LeeHarvard Medical School, Boston, MA, USA.
Erica S ShenoyDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-8086-1123
Harvard University · USMassachusetts General Hospital · USMass General Brigham · US

Funding

CDC HHS NU50CK000622
6 · The paper itself

Abstract

A clinical decision support system, EvalMpox, was developed to apply person under investigation (PUI) criteria for patients presenting with rash and to recommend testing for PUIs. Of 668 patients evaluated, an EvalMpox recommendation for testing had a positive predictive value of 35% and a negative predictive value of 99% for a positive mpox test.

Indexed as

Decision Support Systems, ClinicalDisease OutbreaksExanthemaAdultFemaleHumansMaleMiddle AgedMpox, MonkeypoxPredictive Value of Tests

Identifiers

PMID38561199
PMCPMC11747935
OpenAlexW4393375954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.